Binding and uptake of immunostimulatory CpG oligodeoxynucleotides by human neuroblastoma cells

Oligonucleotides

Volumn 14, Issue 4, 2004, Pages 287-298

  Guo, Liang Hao ^a   Schluesener, Hermann J ^a  

^a UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CELL PROTEIN; OLIGODEOXYNUCLEOTIDE;

ARTICLE; CELLULAR DISTRIBUTION; CONTROLLED STUDY; CPG ISLAND; DNA TRANSFER; DRUG BINDING; ENERGY; HUMAN; HUMAN CELL; INTRACELLULAR TRANSPORT; NEUROBLASTOMA; PRIORITY JOURNAL; TEMPERATURE DEPENDENCE;

EID: 12444339795     PISSN: 15454576     EISSN: None     Source Type: Journal    
DOI: 10.1089/oli.2004.14.287     Document Type: Article

References (42)

1. ANDRATSCHKE, N., GROSU, A.L., MOLLS, M., and NIEDER, C. (2001). Perspectives in the treatment of malignant gliomas in adults. Anticancer Res. 21, 3541-3550.
2. AUF, G., CHEN, L., FORNES, P., LE CLANCHE, C., DELATTRE, J.Y., and CARPENTIER, A.F. (2002). CpG-oligodeoxynucleotide rejection of a neuroblastoma in A/J mice does not induce a paraneoplastic disease. Neurosci. Lett. 327, 189-192.
3. BALLAS, Z.K., KRIEG, A.M., WARREN, T., RASMUSSEN, W., DAVIS, H.L., WALDSCHMIDT, M., and WEINER, G.J. (2001). Divergent therapeutic and immunologic effects of oligodeoxynucleotides with distinct CpG motifs. J. Immunol. 167, 4878-4886.
4. BLANK, M., WEINSCHENK, T., PRIEMER, M., and SCHLUESENER, H.J. (2001). Systematic evolution of a DNA aptamer binding to rat brain tumor microvessels. Selective targeting of endothelial regulatory protein pigpen. J. Biol. Chem. 11, 16464-16468.
5. BRAZOLOT, M.C.L., WEERATNA, R., KRIEG, A.M., SIEGRIST, C.A., and DAVIS, H.L. (1998). CpG DNA can induce strong Th1 humoral and cell-mediated immune responses against hepatitis B surface antigen in young mice. Proc. Natl. Acad. Sci. USA 95, 15553-15558.
6. CARPENTIER, A.F., AUF, G., and DELATTRE, J.Y. (2003). CpG-oligonucleotides for cancer immunotherapy: Review of the literature and potential applications in malignant glioma. Front. Biosci. 8, e115-127.
7. CARPENTIER, A.F., CHEN, L., MALTONTI, F., and DELATTRE, J.Y. (1999). Oligodeoxynucleotides containing CpG motifs can induce rejection of a neuroblastoma in mice. Cancer 59, 5429-5432.
8. CARPENTIER, A.F., XIE, J., MONKHTARI, K., and DELATTRE, J.Y. (2000). Successful treatment of intracranial gliomas in rat by oligodeoxynucleotides containing CpG motifs. Clin. Cancer Res. 6, 2469-2473.
9. CARTER, G., and LEMOINE, N.R. (1993). Antisense technology for cancer therapy: Does it make sense? Br. J. Cancer 67, 869-876.
10. CHU, R.S., TARGONI, O.S., KRIEG, A.M., LEHMANN, P.V., and HARDING, C.V. (1997). CpG oligodeoxynucleotides act as adjuvants that switch on T helper 1 (Th1) immunity. J. Exp. Med. 186, 1623-1631.
11. DALPKE, A.H., ZIMMERMANN, S., ALBRECHT, I., and HEEG, K. (2002). Phosphodiester CpG oligonucleotides as adjuvants: Polyguanosine runs enhance cellular uptake and improve immunostimulative activity of phosphodiester CpG oligonucleotides in vitro and in vivo. Immunology 106, 102-112.
12. HACKER, H., MISCHAK, H., MIETHKE, T., LIPTAY, S., SCHMID, R., SPARWASSER, T., HEEG, K., LIPFORD, G.B., and WAGNER, H. (1998). CpG-DNA-specific activation of antigen-presenting cells requires stress kinase activity and is preceded by non-specific endocytosis and endosomal maturation. EMBO J. 17, 6230-6240.
13. HARTMANN, G., and KRIEG, A.M. (2000). Mechanism and function of a newly identified CpG DNA motif in human primary B cells. J. Immunol. 164, 944-953.
14. HARTMANN, G., KRUG, A., BIDLINGMAIER, M., HACKER, U., EIGLER, A., ALBRECHT, R., STRASBURGER, C.J., and ENDRES, S. (1998). Spontaneous and cationic lipid-mediated uptake of antisense oligonucleotides in human monocytes and lymphocytes. J. Pharmacol. Exp. Ther. 285, 920-928.
15. HAWLEY, P., and GIBSON, I. (1996). Interaction of oligodeoxynucleotides with mammalian cells. Antisense Nucleic Acid Drug Dev. 6, 185-195.
16. HEMMI, H., TAKEUCHI, O., KAWAI, T., KAISHO, T., SATO, S., SANJO, H., MATSUMOTO, M., HOSHINO, K., WAGNER, H., TAKEDA, K., and AKIRA, S. (2000). A toll-like receptor recognizes bacterial DNA. Nature 7, 740-745.
17. KLINMAN, D.M., YI, A.K., BEAUCAGE, S.L., CONOVER, J., and KRIEG, A.M. (1996). CpG motifs present in bacteria DNA rapidly induce lymphocytes to secret interleukin 6, interleukin 12, and interferon gamma. Proc. Natl. Acad. Sci. USA 93, 2879-2883.
18. KRIEG, A.M. (2002). CpG motifs in bacterial DNA and their immune effects. Annu. Rev. Immunol. 20, 709-760.
19. KRIEG, A.M., LOVE-HOMAN, L., YI, A.K., and HARTY, J.T. (1998). CpG DNA induces sustained IL-12 expression in vivo and resistance to Listeria monocytogenes challenge. J. Immunol. 161, 2428-2434.
20. KRIEG, A.M., YI, A.K., MATSON, S., WALDSCHMIDT, T.J., BISHOP, G.A., TEASDALE, R., KORETZKY, G.A., and KLINMAN, D.M. (1995). CpG motifs in bacterial DNA trigger direct B-cell activation. Nature 374, 546-549.
21. LAKTIONOV, P.P., DAZARD, J.E., VIVES, E., RYKOVA, E.Y., PIETTE, J., VLASSOV, V.V., and LEBLEU, B. (1999). Characterisation of membrane oligonucleotide-binding proteins and oligonucleotide uptake in keratinocytes. Nucleic Acids Res. 1, 2315-2324.
22. LIANG, H., REICH, C.F., PISETSKY, D.S., and LIPSKY, P.E. (2001). The role of surface Ig binding in the activation of human B cells by phosphorothioate oligodeoxynucleotides. Scand. J. Immunol. 54, 551-563.
23. LIPFORD, G.B., BAUER, M., BLANK, C., REITER, R., WAGNER, H., and HEEG, K. (1997a). CpG-containing synthetic oligonucleotides promote B and cytotoxic T cell responses to protein antigen: A new class of vaccine adjuvants. Eur. J. Immunol. 27, 2340-2344.
24. LIPFORD, G.B., SPARWASSER, T., BAUER, M., ZIMMERMANN, S., KOCH, E.S., HEEG, K., and WAGNER, H. (1997b). Immunostimulatory DNA: Sequence-dependent production of potentially harmful or useful cytokines. Eur. J. Immunol. 27, 3420-3426.
25. LIPFORD, G.B., SPARWASSER, T., ZIMMERMANN, S., HEEG, K., and WAGNER, H. (2000). CpG-DNA-mediated transient lymphadenopathy is associated with a state of Th1 predisposition to antigen-driven response. J. Immunol. 165, 1228-1235.
26. LOKE, S.L., STEIN, C.A., ZHANG, X.H., MORI, K., NAKANISHI, M., SUBASINGHE, C., COHEN, J.S., and NECKERS, L.M. (1989). Characterization of oligonucleotide transport into living cells. Proc. Natl. Acad. Sci. USA 86, 3474-3478.
27. NOONBERG, S.B., GAROVOY, M.R., and HUNT, C.A. (1993). Characteristics of oligonucleotide uptake in human keratinocyte cultures. J. Invest. Dermatol. 101, 727-731.
28. RANKIN, R., PONTAROLLO, R., IOANNOU, X., KRIEG, A.M., HECKER, R., BABIUK, L.A., and VAN DRUNEN LITTEL-VAN DEN HURK, S. (2001). CpG motif identification for veterinary and laboratory species demonstrates that sequence recognition is highly conserved. Antisense Nucleic Acid Drug Dev. 11, 333-340.
29. SESTER, D.P., NAIK, S., BEASLEY, S.J., HUME, D.A., and STACEY, K.J. (2002). Phosphorothioate backbone modification modulates macrophage activation by CpG DNA. J. Immunol. 15, 4165-4173.
30. SHOJI, Y., AKHTAR, S., PERIASAMY, A., HERMAN, B., and JULIANO, R.L. (1991). Mechanism of cellular uptake of modified oligodeoxynucleotides containing methylphosphonate linkages. Nucleic Acids Res. 19, 5543-5550.
31. SPARWASSER, T., MIETHKE, T., LIPFORD, G., ERDMANN, A., HACKER, H., HEEG, K., and WAGNER, H. (1997). Macrophages sense pathogens via DNA motifs: Induction of tumor necrosis factor alpha mediated shock. Eur. J. Immunol. 27, 1671-1679.
32. STEIN, C.A., and CHENG, Y.C. (1993). Antisense oligonucleotides as therapeutic agents-Is the bullet really magical? Science 261, 1004-1012.
33. STEIN, C.A., SUBASINGHE, C., SHINOZUKA, K., and COHEN, J.S. (1988). Physicochemical properties of phosphorothioate oligodeoxynucleotides. Nucleic Acids Res. 25, 3209-3221.
34. TEMSAMANI, J., KUBERT, M., TANG, J., PADMAPRIYA, A., and AGRAWAL, S. (1994). Cellular uptake of oligodeoxynucleotide phosphorothioates and their analogs. Antisense Res. Dev. 4, 35-42.
35. TONKINSON, J.L., and STEIN, C.A. (1994). Patterns of intracellular compartmentalization, trafficking, and acidification of 5′-fluorescein- labeled phosphodiester and phosphorothioate oligodeoxynucleotides in HL60 cells. Nucleic Acids Res. 22, 4268-4275.
36. WEINER, G.J. (2000). The immunobiology and clinical potential of immunostimulatory CpG oligodeoxynucleotides. J. Leukocyte Biol. 68, 455-463.
37. WEYERBROCK, A., and OLDFIELD, E.H. (1999). Gene transfer technologies for malignant gliomas. Curr. Opin. Oncol. 11, 168-173.
38. WLOCH, M.K., PASQUINI, S., ERTL, H.C., and PISETSKY, D.S. (1998). The influence of DNA sequence on the immunostimulatory properties of plasmid DNA vectors. Hum. Gene Ther. 9, 1439-1447.
39. YI, A.K., KLINMAN, D.M., MARTIN, T.L., MATSON, S., and KRIEG, A.M. (1996). Rapid immune activation by CpG motifs in bacterial DNA. Systemic induction of IL-6 transcription through an antioxidant-sensitive pathway. J. Immunol. 157, 5394-5402.
40. YI, A.K., TUETKEN, R., REDFORD, T., WALDSCHMIDT, M., KIRSCH, J., and KRIEG, A.M. (1998). CpG motifs in bacterial DNA activate leukocytes through the pH-dependent generation of reactive oxygen species. J. Immunol. 160, 4755-4761.
41. ZHAO, Q., MATSON, S., HERRERA, C.J., FISHER, E., YU, H., and KRIEG, A.M. (1993). Comparison of cellular binding and uptake of antisense phosphodiester, phosphorothioate, and mixed phosphorothioate and methylphosphonate oligonucleotides. Antisense Res. Dev. 3, 53-66.
42. ZIMMERMANN, S., EGETER, O., HAUSMANN, S., LIPFORD, G.B., ROCKEN, M., WAGNER, H., and HEEG, K. (1998). CpG oligodeoxynucleotides trigger protective and curative Th1 responses in lethal murine leishmaniasis. J. Immunol. 160, 3627-3630.